Direct Thrombin Inhibitors for the Treatment of Venous Thromboembolism: Analysis of the Dabigatran versus Warfarin Clinical Trial

被引：0

作者：

Liem, Timothy K. ^{[1
]}

DeLoughery, Thomas G. ^{[2
,3
]}

机构：

[1] Oregon Hlth & Sci Univ, Div Vasc Surg, Portland, OR 97239 USA

[2] Oregon Hlth & Sci Univ, Div Hematol Oncol, Portland, OR 97239 USA

[3] Oregon Hlth & Sci Univ, Div Lab Med, Portland, OR 97239 USA

来源：

SEMINARS IN VASCULAR SURGERY | 2011年 / 24卷 / 03期

关键词：

DEEP-VEIN THROMBOSIS; ENOXAPARIN; ETEXILATE; APIXABAN; PREVENTION; THERAPY; THROMBOPROPHYLAXIS; REPLACEMENT;

D O I：

10.1053/j.semvascsurg.2011.11.003

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Vitamin-K antagonists have played a dominant role in the long-term management of patients with venous thromboembolism, and large trials from the past decade reinforced warfarin's effectiveness as an intermediate-duration and extended-duration anticoagulant. However, promising new oral direct thrombin inhibitors are proving to be at least as effective and as safe as the vitamin-K antagonists, without the associated hepatic toxicity that was seen with earlier orally administered direct thrombin inhibitors. This article reviews the recently published Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism clinical trial, and discusses the limitations and clinical applicability of the trial, especially in comparison with vitamin-K antagonists and the recently studied oral direct factor Xa inhibitors, rivaroxaban and apixaban. Semin Vasc Surg 24:157-161 (C) 2011 Published by Elsevier Inc.

引用

页码：157 / 161

页数：5

共 20 条

[1] Oral Rivaroxaban for Symptomatic Venous Thromboembolism. [J].

Bauersachs, Rupert ;

Berkowitz, Scott D. ;

Brenner, Benjamin ;

Buller, Harry R. ;

Decousus, Herve ;

Gallus, Alex S. ;

Lensing, Anthonie W. ;

Misselwitz, Frank ;

Prins, Martin H. ;

Raskob, Gary E. ;

Segers, Annelise ;

Verhamme, Peter ;

Wells, Phil ;

Agnelli, Giancarlo ;

Bounameaux, Henri ;

Cohen, Alexander ;

Davidson, Bruce L. ;

Piovella, Franco ;

Schellong, Sebastian .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (26) :2499-2510

[2] Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study [J].

Buller, H. ;

Deitchman, D. ;

Prins, M. ;

Segers, A. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (08) :1313-1318

[3] Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Eikelboom, John ;

Oldgren, Jonas ;

Parekh, Amit ;

Pogue, Janice ;

Reilly, Paul A. ;

Themeles, Ellison ;

Varrone, Jeanne ;

Wang, Susan ;

Alings, Marco ;

Xavier, Denis ;

Zhu, Jun ;

Diaz, Rafael ;

Lewis, Basil S. ;

Darius, Harald ;

Diener, Hans-Christoph ;

Joyner, Campbell D. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151

[4] Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement:: the RE-MODEL randomized trial [J].

Eriksson, B. I. ;

Dahl, O. E. ;

Rosencher, N. ;

Kurth, A. A. ;

Van Dijk, N. ;

Frostick, S. P. ;

Kalebo, P. ;

Christiansen, A. V. ;

Hantel, S. ;

Hettiarachchi, R. ;

Schnee, J. ;

Buller, H. R. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (11) :2178-2185

[5] Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:: a randomised, double-blind, non-inferiority trial [J].

Eriksson, Bengt I. ;

Dahl, Ola E. ;

Rosencher, Nadia ;

Kurth, Andreas A. ;

van Dijk, C. Niek ;

Frostick, Simon P. ;

Prins, Martin H. ;

Hettiarachchi, Rohan ;

Hantel, Stefan ;

Schnee, Janet ;

Bueller, Harry R. .

LANCET, 2007, 370 (9591) :949-956

[6] Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II) A randomised, double-blind, non-inferiority trial [J].

Eriksson, Bengt I. ;

Dahl, Ola E. ;

Huo, Michael H. ;

Kurth, Andreas A. ;

Hantel, Stefan ;

Hermansson, Karin ;

Schnee, Janet M. ;

Friedman, Richard J. .

THROMBOSIS AND HAEMOSTASIS, 2011, 105 (04) :721-729

[7] Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis -: A randomized trial [J].

Fiessinger, JN ;

Huisman, MV ;

Davidson, BL ;

Bounameaux, H ;

Francis, CW ;

Eriksson, H ;

Lundström, T ;

Berkowitz, SD ;

Nyström, P ;

Thorsén, M ;

Ginsberg, JS .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (06) :681-689

[8] Apixaban versus Warfarin in Patients with Atrial Fibrillation [J].

Granger, Christopher B. ;

Alexander, John H. ;

McMurray, John J. V. ;

Lopes, Renato D. ;

Hylek, Elaine M. ;

Hanna, Michael ;

Al-Khalidi, Hussein R. ;

Ansell, Jack ;

Atar, Dan ;

Avezum, Alvaro ;

Cecilia Bahit, M. ;

Diaz, Rafael ;

Easton, J. Donald ;

Ezekowitz, Justin A. ;

Flaker, Greg ;

Garcia, David ;

Geraldes, Margarida ;

Gersh, Bernard J. ;

Golitsyn, Sergey ;

Goto, Shinya ;

Hermosillo, Antonio G. ;

Hohnloser, Stefan H. ;

Horowitz, John ;

Mohan, Puneet ;

Jansky, Petr ;

Lewis, Basil S. ;

Luis Lopez-Sendon, Jose ;

Pais, Prem ;

Parkhomenko, Alexander ;

Verheugt, Freek W. A. ;

Zhu, Jun ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (11) :981-992

[9]

KEARON C, 2003, NEW ENGL J MED, V349

[10] Antithrombotic therapy for venous thromboembolic disease [J].

Kearon, Clive ;

Kahn, Susan R. ;

Agnelli, Giancarlo ;

Goldhaber, Samuel ;

Raskob, Gary E. ;

Comerota, Anthony J. .

CHEST, 2008, 133 (06) :454S-545S

← 1 2 →